LCM
TPTX

Laurion Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Laurion Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,579
Closed -$812K – 1240
2020
Q2 		$812K Buy
+12,579
New +$726K 0.01% 511
2019
Q3 		– Sell
-75,000
Closed -$3.05M – 1354
2019
Q2 		$3.05M Buy
+75,000
New +$2.68M 0.03% 332

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Laurion Capital Management's TPTX Position: Q3 2020 in Review

Laurion Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2020, closing a stake of 12,579 shares — an estimated $812K sold.

Laurion Capital Management first reported a position in TPTX in Q2 2019 and held it in 2 quarters. The position peaked at $3.05M in Q2 2019. 166 funds tracked by Wall St. Rank hold TPTX as of Q3 2020.

  • Laurion Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Laurion Capital Management sold 12,579 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $812K.
  • Laurion Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Laurion Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.05M in Q2 2019.
  • 166 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Laurion Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.